Compare Globus Medical Inc. Class A Common Stock (GMED) vs Symbotic Inc (SYM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs Symbotic Inc — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while Symbotic Inc trades at $37.42 (market cap $5.31B). The key difference: Globus Medical Inc. Class A Common Stock is the larger of the two by market cap, and Globus Medical Inc. Class A Common Stock is trading nearer its 52-week high, Symbotic Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and Symbotic Inc for 24 Days on average.
| GMED | SYM | |
|---|---|---|
Market Cap | $10.25B | $5.31B |
Volume | 1,108,124 | 1,244,339 |
Sector | Health | Industrials |
52-Week High | $96.82 | $87.30 |
52-Week Low | $58.33 | $37.90 |
Typical Hold Time | 0 Days | 24 Days |
Enterprise Value | $9.76B | $3.56B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
SYM trades at $40.89, down 32% year-to-date and near 52-week lows, with bearish technical signals dominating. Fundamentally, the company shows mixed results with a $22.5 billion backlog and 20%+ revenue growth but negative EBITDA of -$48M and net loss of -$17M in 2025. Recent earnings misses and high customer concentration (85% revenue from Walmart) create uncertainty despite analyst optimism.
The stock presents a high-risk opportunity with significant upside potential if execution improves. Analyst consensus targets $60.33 (47% upside) but near-term risks include continued earnings misses, customer concentration, and weak technical momentum. The 2027 inflection point for new system deployments represents the key growth catalyst.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About Symbotic Inc
Symbotic is an automation technology leader that provides an end-to-end, A.I.-powered robotic platform for large-scale warehouse operations. By utilizing untethered, high-speed autonomous bots and sophisticated vision systems, Symbotic transforms traditional distribution centers into high-density strategic assets. The company serves the world’s largest retailers and wholesalers—most notably Walmart—while expanding into 'Warehouse-as-a-Service' through its GreenBox joint venture to democratize advanced automation for smaller enterprises.
Read more on SYM →
